Immunity Pharma Overview
Immunity Pharma (IPL) develops therapies for neurodegenerative diseases with an initial focus on amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. IPL's drugs are peptides with biologic activity. The peptides stimulate therapeutic cell-signaling processes that are often down-regulated in neurodegenerative diseases. The drugs mitigate disease progression by inducing survival-supporting processes, including reduction of inflammation and reduction of programed cell death (apoptosis). The lead drug, IPL344, is currently entering an open-label, phase-1/2a clinical trial with ALS patients. IPL344 originates from the research laboratory of Professor Irun Cohen at the Weizmann Institute of Science, Israel.
Latest News
growth-positive
Immunity Pharma Announces Promising Interim Results of its Phase 1/2a Study with IPL344 in ALS
Immunity Pharma announced interim results from its Phase 1/2a clinical study with IPL344, a drug for the treatment of ALS. The results showed a potentially favorable impact on patients quality of life and slower disease progression rates. The drug demonstrated a favorable safety and tolerability profile. The study confirmed IPL344s ability to activate the pro-survival Akt pathway in ALS patients. Immunity Pharma plans to continue the collaboration with further development of the drug and is planning a placebo-controlled pivotal trial. IPL344 received orphan drug designation from the FDA and EMA.
Customers
growth-positive
Immunity Pharma ALS drug in clinical trial
Biotechnology company Immunity Pharma has announced the beginning of its first clinical trial for a drug to treat Lou Gehrigs Disease. The drug has shown promise in halting the diseases progression for two years in a compassionate use patient. Immunity Pharmas drug utilizes mechanisms related to the inflammation of nerve cells, which the company believes is the cause of ALS. The company has raised $5 million in funding, including investments from a group of early investors in Mobileye, fund managers, and medical industry specialists.
Investment
growth-positive
Israeli Pharma start-up developing new treatment for ALS
The article discusses the differences between Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS) and the lack of treatment options for ALS, which is considered an orphan disease. However, Immunity Pharma, led by CEO Eran Ovadia, is developing a treatment for ALS based on research by Israeli scientist Irun Cohen. The treatment, which involves the IPL344 peptide, shows promise in slowing the progression of the disease and extending the survival of ALS patients. Immunity Pharma has conducted tests in mice and plans to begin a phase I study by the end of 2012. Ovadia believes that investing in Immunity Pharma could be a smart move for investors, as the odds of a drug reaching the market are better than those for a tech startup.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Pre-Funding |
| Rounds | 0 |
| Investors | 0 |
Team Members
2
Employees: 1-10
Web & Social Links
| Website | immunitypharma.com |
Locations
Meron Street 28, Jerusalem, Israel
Photos & Videos
1 item(s)
Immunity Pharma Business
Business models
B2B
Product stage
Clinical Trial
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsCore Technology
BiologicalsCellsTags (5)
treatmentsdegenerative-diseasespharmaceuticalsamyotrophic-lateral-sclerosis-(als)inflammatory-diseasesGeographic Markets
IsraelImmunity Pharma Financials
Undisclosed
Total funding
—
Capital raised
Undisclosed
Last funding
Pre-Funding
Funding stage
0
Total rounds
0
Investors
Immunity Pharma Lifecycle
Immunity Pharma News
3 articles
growth-positive
Immunity Pharma Announces Promising Interim Results of its Phase 1/2a Study with IPL344 in ALS
Immunity Pharma announced interim results from its Phase 1/2a clinical study with IPL344, a drug for the treatment of ALS. The results showed a potentially favorable impact on patients quality of life and slower disease progression rates. The drug demonstrated a favorable safety and tolerability profile. The study confirmed IPL344s ability to activate the pro-survival Akt pathway in ALS patients. Immunity Pharma plans to continue the collaboration with further development of the drug and is planning a placebo-controlled pivotal trial. IPL344 received orphan drug designation from the FDA and EMA.
Customers
growth-positive
Immunity Pharma ALS drug in clinical trial
Biotechnology company Immunity Pharma has announced the beginning of its first clinical trial for a drug to treat Lou Gehrigs Disease. The drug has shown promise in halting the diseases progression for two years in a compassionate use patient. Immunity Pharmas drug utilizes mechanisms related to the inflammation of nerve cells, which the company believes is the cause of ALS. The company has raised $5 million in funding, including investments from a group of early investors in Mobileye, fund managers, and medical industry specialists.
Investment
growth-positive
Israeli Pharma start-up developing new treatment for ALS
The article discusses the differences between Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS) and the lack of treatment options for ALS, which is considered an orphan disease. However, Immunity Pharma, led by CEO Eran Ovadia, is developing a treatment for ALS based on research by Israeli scientist Irun Cohen. The treatment, which involves the IPL344 peptide, shows promise in slowing the progression of the disease and extending the survival of ALS patients. Immunity Pharma has conducted tests in mice and plans to begin a phase I study by the end of 2012. Ovadia believes that investing in Immunity Pharma could be a smart move for investors, as the odds of a drug reaching the market are better than those for a tech startup.
Investment
Employee Info
| Employees (range) | 1-10 |
| Exact count | 6 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
Immunity Pharma Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 88/100 |
| Missing | funding rounds, markets, external profiles, not claimed |
| BI Verification | Yotam Maman |
| Registrar ID | 513954016 |
| Crunchbase | immunity-pharma-ipl |
| Creator | Yanina Wainscheinker |
| Creator email | yanina.wain@gmail.com |
| Last updater | Paul Weisko |
| Updater email | pweisko@gmail.com |
| Last update | 2021-03-03T00:00:00.000Z |
| Created | 2019-10-21T00:00:00.000Z |